“POTS Adrenergic Ab (CIHR Aims #1&2)”
Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.
Drug - Phenylephrine
incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
Drug - Isoproterenol
incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)